JP2002510978A - 副組織適合性抗原ha―1のタイピング法 - Google Patents
副組織適合性抗原ha―1のタイピング法Info
- Publication number
- JP2002510978A JP2002510978A JP50936899A JP50936899A JP2002510978A JP 2002510978 A JP2002510978 A JP 2002510978A JP 50936899 A JP50936899 A JP 50936899A JP 50936899 A JP50936899 A JP 50936899A JP 2002510978 A JP2002510978 A JP 2002510978A
- Authority
- JP
- Japan
- Prior art keywords
- allele
- primer
- seq
- primers
- typing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims abstract description 81
- 102400000047 Minor histocompatibility antigen HA-1 Human genes 0.000 title claims abstract description 14
- 101800003181 Minor histocompatibility antigen HA-1 Proteins 0.000 title claims abstract description 11
- 101001081189 Homo sapiens Rho GTPase-activating protein 45 Proteins 0.000 claims abstract description 255
- 102100027748 Rho GTPase-activating protein 45 Human genes 0.000 claims abstract description 237
- 108700028369 Alleles Proteins 0.000 claims abstract description 103
- 239000000523 sample Substances 0.000 claims abstract description 77
- 230000003321 amplification Effects 0.000 claims abstract description 46
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 46
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 37
- 239000002773 nucleotide Substances 0.000 claims abstract description 36
- 238000006243 chemical reaction Methods 0.000 claims abstract description 29
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 28
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 28
- 239000012634 fragment Substances 0.000 claims abstract description 21
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims description 58
- 108091007433 antigens Proteins 0.000 claims description 58
- 102000036639 antigens Human genes 0.000 claims description 58
- 238000009396 hybridization Methods 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 238000012163 sequencing technique Methods 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 229940065638 intron a Drugs 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 46
- 208000024908 graft versus host disease Diseases 0.000 description 41
- 208000009329 Graft vs Host Disease Diseases 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 25
- 238000010322 bone marrow transplantation Methods 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 239000000872 buffer Substances 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 239000011651 chromium Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 108010091373 HA-1 antigen Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 108020004635 Complementary DNA Proteins 0.000 description 13
- 238000010804 cDNA synthesis Methods 0.000 description 13
- 230000002441 reversible effect Effects 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 230000009089 cytolysis Effects 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 101001000116 Homo sapiens Unconventional myosin-Ig Proteins 0.000 description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002751 oligonucleotide probe Substances 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102100035824 Unconventional myosin-Ig Human genes 0.000 description 4
- 238000007844 allele-specific PCR Methods 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 238000007399 DNA isolation Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 102000011786 HLA-A Antigens Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000000919 anti-host Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001088879 Homo sapiens Lysine-specific demethylase 5D Proteins 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 206010060872 Transplant failure Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000002593 Y chromosome Anatomy 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- UFFSXJKVKBQEHC-UHFFFAOYSA-N heptafluorobutyric anhydride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(=O)OC(=O)C(F)(F)C(F)(F)C(F)(F)F UFFSXJKVKBQEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 108010032863 HA-2 antigen Proteins 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 108010091938 HLA-B7 Antigen Proteins 0.000 description 1
- 101710082439 Hemagglutinin A Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102100033143 Lysine-specific demethylase 5D Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 201000001322 T cell deficiency Diseases 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 101150011263 Tap2 gene Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 150000001218 Thorium Chemical class 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 102000043813 human MYO1G Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 101150080773 tap-1 gene Proteins 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.サンプル中の副組織適合性抗原HA-1の対立遺伝子のタイピング方法であって 、該対立遺伝子のゲノム核酸またはcDNA中の多形性ヌクレオチドを検出する工程 を含むことを特徴とする、上記方法。 2.該副組織適合性抗原HA-1の該対立遺伝子が、第5図に示すH対立遺伝子およ びR対立遺伝子である、請求の範囲第1項に記載の方法。 3.a)該サンプル中の該ゲノムポリ核酸を、少なくとも1対のプライマーと接触 させ、該少なくとも一対のプライマーの5'−および/または3'−プライマーを、 該対立遺伝子中の多形性ヌクレオチドを含むターゲット領域と特異的にハイブリ ダイズさせ、かつ増幅反応を実施し、 b)該少なくとも1対のプライマー各々について、該工程a)において増幅生成物 が形成されたか否かを検出し、 c)該サンプル中に、どのHA-1の対立遺伝子が存在するかを、該工程b)の結果か ら推定する工程を含む、請求の範囲第1または2項に記載のゲノムタイピング方 法。 4.更に、該少なくとも1対のプライマーが、該HA-1対立遺伝子内の位置4また は位置4および8を含むターゲット領域と特異的にハイブリダイズする5'−プラ イマーを含み、あるいは 該少なくとも1対のプライマーが、該HA-1対立遺伝子内の位置8または位置4 および8を含むターゲット領域と特異的にハイブリダイズする3'−プライマーを 含み、その位置が第5図に示されている、請求の範囲第1〜3項の何れかに記載 の方法。 5.更に、該5'−プライマーが、イントロンa内のターゲット領域と特異的にハ イブリダイズしている、3'−プライマーと組み合わされ、および/または 該3'−プライマーが、エキソンa内のターゲット領域と特異的にハイブリダイ ズする5'−プライマーと組み合わされ、イントロンaおよびエキソンaは第5図 に示されている、請求の範囲第4項に記載の方法。 6.更に、該プライマーが、以下に列挙するものから選択される、請求の範囲第 1〜5項の何れかに記載の方法: 配列番号2、配列番号3、配列番号4、配列番号5、配列番号6、配列番号7 。 7.a)少なくとも一つの多形性ヌクレオチドを含む、該対立遺伝子のフラグメン トを、該対立遺伝子内の保存されたターゲット領域と特異的にハイブリッド化し ている、少なくとも1対のプライマーを使用することにより増幅し、 b)該工程a)の増幅された生成物を、該対立遺伝子内の1以上の多形性ヌクレオ チドを含むターゲット領域と特異的にハイブリダイズする少なくとも1つのプロ ーブとハイブリダイズさせ、 c)該サンプル中に、どのHA-1の対立遺伝子が存在するかを、該工程b)の結果か ら推定する工程を含む、請求の範囲第1または2項に記載のゲノムタイピング方 法。 8.更に、該少なくとも1対のプライマーが、エキソンa内の保存されたターゲ ット領域と特異的にハイブリダイズする5'−プライマーおよび/またはイントロ ンa内の保存されたターゲット領域と特異的にハイブリダイズする3'−プライマ ーを含み、該エキソンaおよび該イントロンaは、第5図に示されているもので ある、請求の範囲第7項に記載の方法。 9.更に、該少なくとも一つのプローブが、該HA-1対立遺伝子内の位置4および /または8に該ヌクレオチドを含む、ターゲット領域と特異的にハイブリッド化 し、該位置が第5図に示された位置である、請求の範囲第7または8項の何れか に記載の方法。 10.更に、該プライマーが、配列番号2、配列番号8、配列番号9、配列番号10 から選択され、および/または該プローブが、配列番号11、配列番号12、配列番 号13、配列番号14、配列番号15、配列番号16から選択されるものである、請求の 範囲第7〜9項の何れかに記載の方法。 11.該副組織適合性抗原HA-1の対立遺伝子をタイピングするための、請求の範囲 第1〜10項の何れかに記載の方法で使用するためのプライマー。 12.該副組織適合性抗原HA-1の対立遺伝子のゲノムタイピングのための、請求の 範囲第7〜10項の何れかに記載の方法で使用するためのプライマー。 13.配列番号1または配列番号17または配列番号18により特定される単離ポリ核 酸、または該ポリ核酸に対して少なくとも80%の配列相同性を示す単離ポリ核酸 、またはHA-1タイピング用のプライマーまたはプローブとして使用することので きる、該ポリ核酸の任意のフラグメント。 14.該対立遺伝子の配列決定による、請求の範囲第1または2項に記載の、該副 組織適合性抗原HA-1の対立遺伝子のゲノムタイピング方法。 15.請求の範囲第3〜6項の何れかに記載の、該副組織適合性抗原HA-1の対立遺 伝子のタイピング用の診断キットであって、 a)請求の範囲第1〜5項の何れかに記載の少なくとも一つのプライマーと、 b)場合により、該増幅反応を可能とする酵素および/または試薬と、 c)場合により、該増幅された生成物の検出を可能とする手段と、 を含むことを特徴とする、上記診断用キット。 16.請求の範囲第7〜10項の何れかに記載の、該副組織適合性抗原HA-1の対立遺 伝子のゲノムタイピング用の診断キットであって、 a)請求の範囲第7〜10項の何れかに記載の少なくとも一つのプライマーと、 b)請求の範囲第7〜10項の何れかに記載の少なくとも一つのプローブと、 c)場合により、該増幅反応を可能とする酵素および/または試薬、および/ま たは該ハイブリッド化反応を可能とする試薬と、 を含むことを特徴とする、上記診断用キット。 17.請求の範囲第14項記載の、該副組織適合性抗原HA-1の対立遺伝子のゲノムタ イピング用の診断キットであって、 a)必須の、請求の範囲第7〜10項の何れかに記載の少なくとも一つのプライマ ーと、 b)場合により、該増幅反応を可能とする酵素および/または試薬、および/ま たは該配列決定反応を可能とする試薬と、 を含むことを特徴とする、上記診断用キット。 18.第5図に示した、HA-1の対立遺伝子を特異的に検出する抗体を使用する工程 を含むことを特徴とする、該HA-1の対立遺伝子をタイピングする方法。 19.第5図に示した、HA-1の対立遺伝子を特異的に検出する抗体を含むことを特 徴とする、該HA-1の対立遺伝子をタイピングするための診断用キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97202303 | 1997-07-23 | ||
EP97202303.0 | 1997-07-23 | ||
EP98870125.6 | 1998-06-02 | ||
EP98870125A EP0965648A1 (en) | 1998-06-02 | 1998-06-02 | Method for genomic typing of the Minor Histocomptability Antigen HA-1. |
PCT/EP1998/004928 WO1999005313A2 (en) | 1997-07-23 | 1998-07-23 | Method for typing of minor histocompatibility antigen ha-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002510978A true JP2002510978A (ja) | 2002-04-09 |
JP2002510978A5 JP2002510978A5 (ja) | 2006-01-05 |
Family
ID=26146730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50936899A Ceased JP2002510978A (ja) | 1997-07-23 | 1998-07-23 | 副組織適合性抗原ha―1のタイピング法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6830883B1 (ja) |
EP (1) | EP0966545B1 (ja) |
JP (1) | JP2002510978A (ja) |
AT (1) | ATE315103T1 (ja) |
AU (1) | AU732952B2 (ja) |
CA (1) | CA2266456A1 (ja) |
DE (1) | DE69833120T2 (ja) |
DK (1) | DK0966545T3 (ja) |
ES (1) | ES2256953T3 (ja) |
WO (1) | WO1999005313A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0996636B1 (en) | 1997-07-23 | 2005-01-26 | Rijksuniversiteit te Leiden | The ha-1 antigen |
DK0966545T3 (da) * | 1997-07-23 | 2006-05-22 | Univ Leiden | Fremgangsmåde til typebestemmelse af minor histokompatibilitetsantigen HA-1 |
US20040092446A1 (en) * | 1997-07-23 | 2004-05-13 | Goulmy Elsa A.J.M. | HA-1 epitopes and uses thereof |
GB0128153D0 (en) * | 2001-11-23 | 2002-01-16 | Bayer Ag | Profiling of the immune gene repertoire |
JP2005529187A (ja) | 2002-06-13 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 同種抗原の特定方法、ならびに癌治療および移植へのその使用 |
EP2803363B1 (en) | 2013-05-13 | 2017-04-05 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | The antigen CYBA-72Y/B15 and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0578397A (ja) * | 1991-01-29 | 1993-03-30 | Sumitomo Pharmaceut Co Ltd | 血栓溶解タンパク質 |
CA2081582A1 (en) * | 1991-11-05 | 1993-05-06 | Teodorica Bugawan | Methods and reagents for hla class i dna typing |
US5567583A (en) * | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
AU726441B2 (en) * | 1995-08-21 | 2000-11-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods of assessing MHC class I expression and proteins capable of modulating class I expression |
WO1998026091A2 (en) * | 1996-12-12 | 1998-06-18 | Visible Genetics, Inc. | Method and kit for hla class i typing |
DK0966545T3 (da) * | 1997-07-23 | 2006-05-22 | Univ Leiden | Fremgangsmåde til typebestemmelse af minor histokompatibilitetsantigen HA-1 |
-
1998
- 1998-07-23 DK DK98942664T patent/DK0966545T3/da active
- 1998-07-23 AU AU90713/98A patent/AU732952B2/en not_active Ceased
- 1998-07-23 CA CA002266456A patent/CA2266456A1/en not_active Abandoned
- 1998-07-23 AT AT98942664T patent/ATE315103T1/de not_active IP Right Cessation
- 1998-07-23 JP JP50936899A patent/JP2002510978A/ja not_active Ceased
- 1998-07-23 ES ES98942664T patent/ES2256953T3/es not_active Expired - Lifetime
- 1998-07-23 US US09/269,250 patent/US6830883B1/en not_active Expired - Fee Related
- 1998-07-23 DE DE69833120T patent/DE69833120T2/de not_active Expired - Fee Related
- 1998-07-23 EP EP98942664A patent/EP0966545B1/en not_active Expired - Lifetime
- 1998-07-23 WO PCT/EP1998/004928 patent/WO1999005313A2/en active IP Right Grant
-
2004
- 2004-12-08 US US11/007,740 patent/US20050233350A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU9071398A (en) | 1999-02-16 |
ES2256953T3 (es) | 2006-07-16 |
DE69833120T2 (de) | 2007-03-01 |
WO1999005313A2 (en) | 1999-02-04 |
WO1999005313A3 (en) | 1999-04-15 |
CA2266456A1 (en) | 1999-02-04 |
EP0966545B1 (en) | 2006-01-04 |
US20050233350A1 (en) | 2005-10-20 |
AU732952B2 (en) | 2001-05-03 |
DK0966545T3 (da) | 2006-05-22 |
US6830883B1 (en) | 2004-12-14 |
ATE315103T1 (de) | 2006-02-15 |
EP0966545A2 (en) | 1999-12-29 |
DE69833120D1 (de) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Akatsuka et al. | Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens | |
Tokunaga et al. | Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes | |
Okamura et al. | The most primitive vertebrates with jaws possess highly polymorphic MHC class I genes comparable to those of humans | |
Dolstra et al. | Bi‐directional allelic recognition of the human minor histocompatibility antigen HB‐1 by cytotoxic T lymphocytes | |
Douillard et al. | Donor-specific blood transfusion-induced tolerance in adult rats with a dominant TCR-Vbeta rearrangement in heart allografts. | |
Muczynski et al. | Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium | |
Price et al. | Heritable factors distinguish two types of alopecia areata | |
Tatari et al. | HLA-Cw allele analysis by PCR-restriction fragment length polymorphism: study of known and additional alleles. | |
Wilke et al. | Genomic identification of the minor histocompatibility antigen HA‐1 locus by allele‐specific PCR | |
Mouro et al. | Molecular basis of the RhCW (Rh8) and RhCX (Rh9) blood group specificities | |
Antao et al. | Genomic organization and differential expression of channel catfish MHC class I genes | |
AU695801B2 (en) | Interaction of T-cell receptors and antigen in autoimmune disease | |
JP2003504005A (ja) | T細胞レセプターVβ−Dβ−Jβ配列およびその検出法 | |
Garber et al. | HLA-B alleles of the Cayapa of Ecuador: new B39 and B15 alleles | |
Liu et al. | Xenopus class II A genes: studies of genetics, polymorphism, and expression | |
JP2002510978A (ja) | 副組織適合性抗原ha―1のタイピング法 | |
JP2001511363A (ja) | レトロウイルスの超抗原を含むインスリン依存性真性糖尿病のごとき自己免疫疾患の診断および治療方法 | |
Penfornis et al. | Analysis of TAP2 polymorphisms in Finnish individuals with type I diabetes | |
Saeki et al. | Analysis of HLA class II and TAP alleles in Japanese patients with psoriasis vulgaris | |
Chevrier et al. | Idiopathic and secondary membranous nephropathy and polymorphism at TAP1 and HLA‐DMA loci | |
Hirv et al. | Disulfide bridge disruption in the α2 domain of the HLA class I molecule leads to low expression of the corresponding antigen | |
CA2418676A1 (en) | 21 human secreted proteins | |
Loveland et al. | The definition and expression of minor histocompatibility antigens | |
Ogawa et al. | Identification of the gene encoding a novel HLA-B39 subtype Two amino acid substitutions on the β-sheet out of the peptide-binding floor form a novel serological epitope | |
Chevrier et al. | Impact of the MHC-encoded HLA-DMA, DMB, and LMP2 gene polymorphisms on kidney graft outcome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20050721 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |